KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Work In Process: 2018-2025

Historic Work In Process for Rigel Pharmaceuticals (RIGL) over the last 8 years, with Sep 2025 value amounting to $5.5 million.

  • Rigel Pharmaceuticals' Work In Process rose 202.98% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year increase of 202.98%. This contributed to the annual value of $1.2 million for FY2024, which is 34.65% down from last year.
  • As of Q3 2025, Rigel Pharmaceuticals' Work In Process stood at $5.5 million, which was up 170.43% from $2.0 million recorded in Q2 2025.
  • Rigel Pharmaceuticals' Work In Process' 5-year high stood at $6.0 million during Q2 2024, with a 5-year trough of $162,000 in Q4 2021.
  • Moreover, its 3-year median value for Work In Process was $2.0 million (2023), whereas its average is $2.9 million.
  • In the last 5 years, Rigel Pharmaceuticals' Work In Process plummeted by 86.38% in 2021 and then surged by 1,541.36% in 2022.
  • Quarterly analysis of 5 years shows Rigel Pharmaceuticals' Work In Process stood at $162,000 in 2021, then soared by 1,541.36% to $2.7 million in 2022, then dropped by 29.45% to $1.9 million in 2023, then slumped by 34.65% to $1.2 million in 2024, then surged by 202.98% to $5.5 million in 2025.
  • Its Work In Process was $5.5 million in Q3 2025, compared to $2.0 million in Q2 2025 and $1.1 million in Q1 2025.